Who Paid My Doc
John Branda
Anatomic Pathology & Clinical Pathology Boston, MA Medical Doctor
NPI 1104809573 CMS profile 651054
55 Fruit St, Grb 526, Clinical Microbiology, Boston, MA 02114
General payments
$23,347
Research payments
$2,000
Ownership & investment interest
$0
Research they led as principal investigator
$86,468
Through program year 2022, John Branda of Boston, MA is reported in the CMS Open Payments database as having received $23,347 across 18 general payments and $2,000 in research payments paid to them. Separately, studies naming them as principal investigator received $86,468 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $104 | 1 | |
| 2019 | General | $23,243 | 17 | |
| 2019 | Research | $2,000 | 1 |
Beside peers
- John Branda
- Anatomic Pathology & Clinical Pathology median
- Middle half of Anatomic Pathology & Clinical Pathology
- National median
In program year 2025, general payments to John Branda were reported at $0. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.
Show as a table
| Year | John Branda | Anatomic Pathology & Clinical Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $23,243 | $65 | $22–$150 | $163 |
| 2020 | $0 | $44 | $19–$144 | $114 |
| 2021 | $0 | $42 | $19–$142 | $132 |
| 2022 | $104 | $54 | $20–$140 | $149 |
| 2023 | $0 | $60 | $23–$157 | $160 |
| 2024 | $0 | $51 | $23–$145 | $164 |
| 2025 | $0 | $51 | $24–$149 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anatomic Pathology & Clinical Pathology in Massachusetts
Jason Baron
Anatomic Pathology & Clinical Pathology · Boston, MA
Thomas Gould
Anatomic Pathology & Clinical Pathology · Holyoke, MA
Rosina Lis
Anatomic Pathology & Clinical Pathology · Westborough, MA
Manlio Loconte
Anatomic Pathology & Clinical Pathology · Boston, MA
Gretchen Frieling
Anatomic Pathology & Clinical Pathology · Wellesley Hills, MA
Franklin Moore
Anatomic Pathology & Clinical Pathology · Springfield, MA
Related records
Anatomic Pathology & Clinical Pathology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Anatomic Pathology & Clinical Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.